Author:
van Veen Anneloes,de Goeij Inge,Damen Marjolein,Huijskens Elisabeth G.W.,Paltansing Sunita,van Rijn Michiel,Bentvelsen Robbert G.,Veenemans Jacobien,van der Linden Michael,Vos Margreet C.,Severin Juliëtte A.
Abstract
SummaryBackgroundContact precautions (CP) are recommended when caring for patients with carbapenemase-producing Enterobacterales (CPE), carbapenemase-producingPseudomonas aeruginosa(CPPA), and extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E).AimOur aim was to determine the interpretation of CP and associated infection prevention and control (IPC) measures in the non-ICU hospital setting for patients with CPE, CPPA or ESBL-E in 11 hospitals in the Southwest of the Netherlands.MethodsA cross-sectional survey was developed to collect information on all implemented IPC measures, including use of personal protective equipment, IPC measures for visitors, cleaning and disinfection, precautions during outpatient care and follow-up strategies. All eleven hospitals were invited to participate between November 2020 and April 2021.FindingsThe survey was filled together with each hospital. All hospitals installed isolation precautions for patients with CPE and CPPA during inpatient care and day admissions, whereas ten hospitals (90.9%) applied isolation precautions for patients with ESBL-E. Gloves and gowns were always used during physical contact with the patient in isolation. Large variations were identified in IPC measures for visitors, cleaning and disinfection products used, and precautions during outpatient care. Four hospitals (36.4%) actively followed up on CPE or CPPA patients with the aim to declare them CPE- or CPPA-negative as timely as possible, and two hospitals (20.0%) actively followed up on ESBL-E patients.ConclusionCP are interpreted differently between hospitals, leading to regional differences in IPC measures applied in clinical settings. Harmonizing infection-control policies between the hospitals could facilitate patient transfers and benefit collective efforts of preventing transmission of MDR-GNB.
Publisher
Cold Spring Harbor Laboratory
Reference39 articles.
1. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
2. Attributable Mortality Rate for Carbapenem-Resistant Klebsiella pneumoniae Bacteremia
3. Epidemiology and characterisation of carbapenem-non-susceptible Pseudomonas aeruginosa in a large intensive care unit in Jakarta, Indonesia;Int J Antimicrob Agents,2019
4. Nethmap/MARAN. NethMap 2021: Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands. 2021.
5. European Centre for Disease Prevention and Control. European Antimicrobial Resistance Surveillance Network (EARS-Net), https://www.ecdc.europa.eu/en/about-us/networks/disease-networks-and-laboratory-networks/ears-net-data; 2021 [accessed April 4 2023.].